136 related articles for article (PubMed ID: 33306339)
1. Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment.
Tan Y; Li Y; Qu YX; Su Y; Peng Y; Zhao Z; Fu T; Wang XQ; Tan W
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9436-9444. PubMed ID: 33306339
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
4. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
5. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.
Huang YF; Shangguan D; Liu H; Phillips JA; Zhang X; Chen Y; Tan W
Chembiochem; 2009 Mar; 10(5):862-8. PubMed ID: 19253922
[TBL] [Abstract][Full Text] [Related]
6. Targeting breast cancer stem cells by a self-assembled, aptamer-conjugated DNA nanotrain with preloading doxorubicin.
Xu Z; Ni R; Chen Y
Int J Nanomedicine; 2019; 14():6831-6842. PubMed ID: 31695364
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
8. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
9. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
Joshi M; Choi JS; Park JW; Doh KO
J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
[TBL] [Abstract][Full Text] [Related]
10. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
[TBL] [Abstract][Full Text] [Related]
11. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.
Mondal L; Mukherjee B; Das K; Bhattacharya S; Dutta D; Chakraborty S; Pal MM; Gaonkar RH; Debnath MC
Int J Nanomedicine; 2019; 14():8073-8094. PubMed ID: 31632019
[TBL] [Abstract][Full Text] [Related]
12. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
13. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional Bioconjugate for Cancer Cell-Targeted Theranostics.
Du W; Yuan Y; Wang L; Cui Y; Wang H; Xu H; Liang G
Bioconjug Chem; 2015 Dec; 26(12):2571-8. PubMed ID: 26580576
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.
Dai B; Hu Y; Duan J; Yang XD
Oncotarget; 2016 Jun; 7(25):38257-38269. PubMed ID: 27203221
[TBL] [Abstract][Full Text] [Related]
18. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
20. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer.
Li X; Wu X; Yang H; Li L; Ye Z; Rao Y
Biomed Pharmacother; 2019 Sep; 117():109072. PubMed ID: 31202169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]